New drug trial targets common kidney disease
NCT ID NCT06830395
Summary
This study is testing an experimental injection called CM313 for people with IgA nephropathy, a kidney disease. Researchers want to see if the drug is safe and effective at controlling the disease. The trial will enroll about 106 adults who have already been on standard blood pressure medications but still have significant protein in their urine.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IGA NEPHROPATHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Peking University First Hospital
Beijing, Beijing Municipality, China
Conditions
Explore the condition pages connected to this study.